Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET EXON 14 SKIPPING MUTATION
MET EXON 14 SKIPPING MUTATION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7272
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/324
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Tepotinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Drugs
Drug NameSensitivitySupported
TepotinibSensitivitytrue